Process for synthesizing lornoxicam intermediate against inflammation and pain

Abstract

Disclosed is a process for synthesizing lornoxicam intermediate against inflammation and pain, which comprises using 5-chloro-3-thiophene sulfonyl chloride-2-carboxylate as raw material, charging 2-10% of sodium carbonate aqueous solution and 5-30% of glycine methylester hydrochloride simultaneously into water and methanol phases, thermal insulating 6-26 hours at 10-60 deg. C, then filtering and drying to obtain 6-chloro-3-sulfamoyl amido methyl acetate thiophene-2 methyl formate, reacting it with 5-27% of sodium methylate methanol solution 1-15 hours at 30-75 deg. C, filtering to obtain 6-chloro-4-hydroxyl-2H-thione[2,3-e]-1 and 2-thiazine-3-methyl formate-1,1-dioxide, then reacting the filtered substance with dimethyl sulfate in 1-10% aqueous solution of sodium-hydroxide.

Description

technical field

[0001] The present invention relates to a compound synthesis method, specifically a 6-chloro-4-hydroxyl-2-methyl-2H-thieno[2,3-e]-1,2-thiazine-3-carboxylic acid methyl ester- A synthesis method of 1,1-dioxide, which is used to synthesize the anti-inflammatory and analgesic drug lornoxicam. Background technique

[0002] The anti-inflammatory analgesic drug Lornoxicam Lomoxicam is a selective cyclooxygenase inhibitor non-steroidal anti-inflammatory analgesic drug developed by Norway Nycomed Company. It was first launched in Denmark in October 1997 and has been sold in more than 30 countries worldwide It has been listed in the country and included in the analgesic ladder program formulated by the World Health Organization. In 2002, domestic import sales were approved. This product has powerful anti-inflammatory and analgesic effects; it can be taken orally or injected, and is mainly used for the treatment of mild to moderate pain caused by rheumatoid arthritis...

Images